(2S)-2-氨基-4-(2-氨基-3-氯苯基)-4-氧代丁酸 | 855634-17-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: (2S)-2-氨基-4-(2-氨基-3-氯苯基)-4-氧代丁酸
• 英文名称: 3-chloro-4-hydroxy-quinoline-2-carboxylic acid
• 英文别名: 3-Chlor-4-hydroxy-chinolin-2-carbonsaeure；3-Chloro-4-oxo-1,4-dihydroquinoline-2-carboxylic acid；3-chloro-4-oxo-1H-quinoline-2-carboxylic acid
• CAS: 855634-17-2
• 化学式: C₁₀H₆ClNO₃
• 分子量: 223.616
• InChiKey: FBUCGCVFOMBTRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S)-2-氨基-4-(2-氨基-3-氯苯基)-4-氧代丁酸 在 二苯醚 、 联苯 作用下， 生成 3-氯喹啉-4-醇
  参考文献：
  名称：

  The Preparation of 3-Halo-4-dialkylaminoalkylaminoquinoline Derivatives

  摘要：

  DOI：

  10.1021/ja01216a044
• 作为产物：
  描述：

  4-羟基-2-乙基喹啉羧酸酯 在 sodium hydroxide 、 磺酰氯 、 碘 、 乙酸酐 、 溶剂黄146 作用下， 生成 (2S)-2-氨基-4-(2-氨基-3-氯苯基)-4-氧代丁酸
  参考文献：
  名称：

  The Preparation of 3-Halo-4-dialkylaminoalkylaminoquinoline Derivatives

  摘要：

  DOI：

  10.1021/ja01216a044

文献信息

• Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
  申请人：G.D. Searle & Co.

  公开号：EP0396124A2

  公开（公告）日：1990-11-07

  Compositions containing certain indole-2-carboxylate compounds and derivatives are described as being therapeutically effective in treatment of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases, particularly those CNS disorders resulting from ischemic events. Preferred compounds are of the formula wherein each of R5 and R6 is independently selected from hydrido, bromo, chloro and fluoro, and wherein each of R10 and R12 is independently selected from hydride and lower alkyl, and pharmaceutically-acceptable salts thereof.

  据描述，含有某些吲哚-2-羧酸盐化合物和衍生物的组合物对治疗神经毒性损伤或神经退行性疾病导致的中枢神经系统疾病，特别是缺血性事件导致的中枢神经系统疾病具有治疗效果。优选的化合物如下式所示 其中 R5 和 R6 各自独立地选自氢基、溴基、氯基和氟基，R10 和 R12 各自独立地选自氢基和低级烷基，及其药学上可接受的盐。
• Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
  申请人：Olney, John William

  公开号：EP0424179A2

  公开（公告）日：1991-04-24

  The neurotoxic effects of NMDA antagonists are reduced by administering, in conjunction with an NMDA antagonist, an anti-cholinergic agent which is capable of penetrating the blood-brain barrier and which exerts a pharmaceutically antagonistic effect on cholinergic receptors of the muscarinic type on the surfaces of neurons in the central nervous system. Also, excitotoxic damage to neurons in a mammalian central nervous system is reduced by the administration of: (a) an NMDA antagonist which penetrates blood-brain barriers in quantities sufficient to inhibit the functioning of NMDA receptors; and (b) a non-NMDA antagonist which penetrates blood-brain barriers in quantities sufficient to inhibit the functioning of at least one type of non-NMDA receptor.

  在使用 NMDA 拮抗剂的同时，还可以使用一种抗胆碱能药物，这种药物能够穿透血脑屏障，并对中枢神经系统神经元表面的毒蕈碱型胆碱能受体产生药理拮抗作用，从而减少 NMDA 拮抗剂的神经毒性作用。此外，哺乳动物中枢神经系统神经元的兴奋毒性损伤也可通过服用以下药物而减轻： (a) 一种 NMDA 拮抗剂，它能穿透血脑屏障，足以抑制 NMDA 受体的功能；以及 (b) 非 NMDA 拮抗剂，其穿透血脑屏障的量足以抑制至少一种非 NMDA 受体的功能。
• Methods and compositions for treating cancer using P2RX2 inhibitors
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US10457740B1

  公开（公告）日：2019-10-29

  The present invention provides methods for treating cancer using P2RX2 inhibitors, such as P2RX2 inhibitory antibodies, among others. The invention also features compositions containing P2RX2 inhibitors, methods of diagnosing patients with P2RX2-associated cancer, and methods of predicting the response of cancer in a subject to treatment with P2RX2 inhibitors.

  本发明提供了使用 P2RX2 抑制剂（如 P2RX2 抑制抗体等）治疗癌症的方法。本发明还包括含有 P2RX2 抑制剂的组合物、诊断 P2RX2 相关癌症患者的方法以及预测癌症对 P2RX2 抑制剂治疗的反应的方法。
• Methods for treating cancer using GRM8 inhibitors
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US10683352B1

  公开（公告）日：2020-06-16

  The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.

  本发明提供了使用mGluR8抑制剂（如mGluR8抑制抗体和小分子）治疗癌症的方法。本发明还包括含有 mGluR8 抑制剂的组合物、诊断 mGluR8 相关癌症患者的方法以及预测癌症对 mGluR8 抑制剂治疗的反应的方法。
• Methods and compositions for treating cancer using SERCA pump inhibitors
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US11013717B1

  公开（公告）日：2021-05-25

  The present invention provides methods for treating cancer using sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors, such as SERCA pump inhibitory antibodies, among others. The invention also features compositions containing SERCA pump inhibitors, methods of diagnosing patients with SERCA pump-associated cancer, and methods of predicting the response of cancer in a subject to treatment with SERCA pump inhibitors.

  本发明提供了使用肌浆/内质网Ca2+-ATP酶（SERCA）泵抑制剂（如SERCA泵抑制抗体等）治疗癌症的方法。本发明还包括含有 SERCA 泵抑制剂的组合物、诊断 SERCA 泵相关癌症患者的方法以及预测癌症对 SERCA 泵抑制剂治疗的反应的方法。